Foundation Medicine to Present at Upcoming Investor Conferences
Get Alerts FMI Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ: FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:
- Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016 at 10:00 a.m. P.T. in Las Vegas.
- UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 3:00 p.m. E.T. in New York City.
Live, listen-only webcasts of the presentations may be accessed by visiting the investors section of the company’s website at investors.foundationmedicine.com. Replays of the webcasts will be available shortly after the conclusion of the presentations and will be archived on the company's website for 90 days.
About Foundation Medicine
Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160428005148/en/
Media Contact:
Pure Communications, Inc.
Dan Budwick,
973-271-6085
[email protected]
or
Investor
Contact:
Kimberly Brown, 617-418-2215
[email protected]
Source: Foundation Medicine, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
- reAlpha Tech Corp. Announces Financial Results for the Quarter Ended March 31, 2024
- Cresset Welcomes Two New Advisory Teams, Expands National Presence and San Francisco Footprint
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
UBS, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!